Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is a promising company with a strong focus on developing oral, small molecule drugs for metabolic diseases such as diabetes and obesity. With a potentially effective drug candidate in icovamenib and a pipeline of other promising drugs, the company has significant potential for growth in the competitive diabetes market. However, the success of icovamenib will depend on the results of larger clinical trials and competition from other companies in the space.

Bears say

Biomea Fusion is a clinical-stage company focused on the development of oral, small molecule drugs for the treatment of diabetes, obesity, and metabolic diseases. While the potential for its lead drug candidate, icovamenib, to improve outcomes in diabetes and obesity is supported by compelling early data, the small sample size and upcoming Phase 2b data in 4Q26 creates uncertainty around its future prospects. Additionally, the company's other drug candidate, BMF-650, has potential upside but faces competition in the crowded GLP market and has yet to report data in its Phase 1 trial. The overall risk/reward for the company may skew positively from current levels, but there are still several key catalysts to watch in the coming quarters.

BMEA has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 4 analysts, BMEA has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.